SEC Form 4 · accession 0001209191-18-045509
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Aug 2, 2018
Accepted (ET)
Aug 6, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 2, 2018 | M | 7,000 | $5.5004 | A | 31,905 | D | |
| Common StockF2 | Aug 2, 2018 | S | 5,790 | $150.1773 | D | 26,115 | D | |
| Common StockF3 | Aug 2, 2018 | S | 1,110 | $151.2149 | D | 25,005 | D | |
| Common Stock | Aug 2, 2018 | S | 100 | $152.10 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $5.5004 | Aug 2, 2018 | M | 7,000 | D | — | Jan 16, 2023 | Common Stock | 7,000 | 43,951 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
- F2The range in prices for the transaction reported on this line was $150.00 to $150.90. The average weighted price was $150.1773. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $151.00 to $151.60. The average weighted price was $151.2149. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.